Milestone Pharmaceuticals Inc. has officially filed its FORM S-1 with The Securities and Exchange Commission (SEC) in connection with its proposed initial public offering (IPO).
Jefferies, Cowen and Piper Jaffray act as Joint Book-Running Managers.
Cooley LLP and Osler, Hoskin & Harcourt LLP act as US and Canaidan legal counsel respectively to Milestone while Wilmer Cutler Pickering Hale and Dorr LLP and McCarthy Tétrault LLP are acting as US and Canadian legal counsel to the underwriters.
Milestone Pharmaceuticals have applied to list our common shares on The Nasdaq Global Market under the symbol “MIST”. The company had previously filed a draft registration statement on December 21, 2018, seeking to list its shares on NASDAQ under “MSPH”.
Milestone Pharmaceuticals is backed by RTW Investments, LP, Novo Holdings, A/S, Fonds de solidarité FTQ, BDC Capital, Venrock, Domain Associates, Pappas Capital and Forbion which collectively control 86.5% of pre-IPO shares.
Milestone Pharmaceuticals has raised US $140 million in Series A-D financings from the backers since its inception in 2003.
Montreal based Milestone Pharmaceuticals Inc. is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent short-acting calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia as they occur.